D. Boral Capital Reaffirms Buy Rating for Can-Fite BioPharma (NYSE:CANF)
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. Separately, StockNews.com began coverage on Can-Fite BioPharma in a research report on Saturday, March 15th. They […]
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. Separately, StockNews.com began coverage on Can-Fite BioPharma in a research report on Saturday, March 15th. They […]
